Aperçu

Éligibilité

Détails de la conception

Bras et interventions

Mesures des résultats

Sites d'essai

Source : NCT04673955

Recrutement en cours

BERING-CRC: BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

Observationnel

Phase non listée

Hospital

Sponsor: Pierre Fabre

Dernière synchronisation : 29 septembre 2022
Avis - Les informations proviennent de registres publics et peuvent ne pas refléter les changements en temps réel sur le site local.

The presence of a BRAFV600E mutation is a marker of poor prognosis in patients with mCRC and associated with a median overall survival (mOS) of approximately 12 to 14 months compared to 20 to 25 months for patients with BRAF wild-type tumours. After 1st line therapy, treatment outcomes with standard therapy are poor in patients with BRAF-mutated mCRC, with response rates (ORR) of ≤ 11%, a median progression-free survival (mPFS) between 1.8 and 2.8 months, and a mOS between 4.1 and 6.2 months. Failure to achieve adequate survival outcomes with standard treatment regimens in patients with BRAF-mutated mCRC has encouraged efforts to combine multiple targeted therapies: With 665 randomized patients, the BEACON CRC trial represents the largest trial and is currently the only phase III study in patients with BRAFV600E-mutant mCRC.

BERING CRC - designed as a prospective (allowing initial retrospective documentation), longitudinal, non-interventional study - will investigate the real-world effectiveness, quality of life, safety and tolerability of encorafenib and cetuximab in BRAFV600E-mutant mCRC patients, who have received prior systemic therapy. Data from this study will contribute to a deeper understanding and characterization to the everyday use of encorafenib and cetuximab in a broader patient population in the German, Austrian, and Swiss routine setting.

Afficher la description détaillée

Catégorie de traitement

Anticorps monoclonaux, Thérapie ciblée

Mutations requises

BRAF

Essai commencé

3 septembre 2020

Dernière mise à jour par le sponsor

29 septembre 2022

Achèvement estimé

1 septembre 2026

Contact de l'étude

Nom:Marion Schmoll

E-mail:marion.schmoll@iomedico.com

Téléphone:+4976115242627

Nom:Frank Reichenbach, Dr. rer. nat

E-mail:frank.reichenbach@pierre-fabre.com

Téléphone:+4976145261846

Éligibilité

Critères d'inclusion

* Written informed consent of the patient with regard to the pseudonymized documentation of his/her data in the frame of this non-interventional study

* Legally capable patient ≥ 18 years of age (no upper limit)

* Metastatic colorectal carcinoma with BRAFV600E-mutation, pretreated with systemic therapy

* Decision was taken to treat the patient with the doublet therapy (encorafenib and cetuximab) in accordance with the current SmPC and by prescription; this decision was taken prior to and independent from the inclusion into the study;

* Treatment with the doublet therapy (encorafenib plus cetuximab) has been started ≤ 3 months prior to providing written informed consent for this study or is planned to be started in the near future.

Critères d'exclusion

* More than 2 prior systemic regimens in the metastatic setting (adjuvant systemic therapy with relapse ≤ 6 months will be counted as metastatic treatment line; maintenance treatment will not be counted as separate metastatic treatment line)

* Prior treatment with any RAF-inhibitor or MEK-inhibitor.

* Presence of any contraindication with regard to the doublet therapy (encorafenib plus cetuximab) as specified in the corresponding SmPCs

* Current or upcoming participation in an interventional clinical trial

* Current or upcoming systemic treatment of any other tumor than metastatic colorectal carcinoma

* Prisoners or persons who are compulsorily detained (involuntarily incarcerated).

Pensez-vous que cet essai apparaît incorrectement ?

Détails de la conception

AllocationN/A

Modèle d'interventionN/A

MasquageN/A

Nombre à inscrire500

Bras et interventions

Bras

Interventions

Aucune intervention disponible.

Mesures des résultats

Mesures des résultats primaires

Overall SurvivalAt 12 months after start of treatment

Overall Survival rate

Mesures des résultats secondaires

Patient and disease profiles at start of treatment with encorafenib plus cetuximabBaseline

Demographic and disease chracteristics

BRAF-mutation assessmentBaseline

Date and type of BRAFV600E testing

Type and sequence of treatments before and after encorafenib plus cetuximabThrough study completion, an average of 17 months

Treatment sequence prior to and after encorafenib plus cetuximab

Characteristics of treatment with encorafenib plus cetuximabThrough encorafenib plus cetuximab treatment completion, an average of 9 months

Evaluation of reason for treatment selection (efficacy, safety profile, quality of life, patients preference, physician's preference, comorbidities, other)